Several studies suggested that LRRC37A2 is implicated in epilepsy, epileptic encephalopathy, and Parkinson’s disease, while the effect on DLBCL has never been reported (Yao et al., 2021). This evidence concerns the gene LRRC37A2 and diffuse large B-cell lymphoma.